We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tiziana Life Sciences Plc | LSE:TILS | London | Ordinary Share | GB00BKWNZY55 | ORD 3P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 58.50 | 45.00 | 60.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
09/9/2014 01:24 | Sign me up! LOL! | stav5001 | |
08/9/2014 10:42 | yes meets every 10p rise | rovi67 | |
02/9/2014 17:25 | Do we have a fan club here? | stav5001 | |
28/8/2014 19:26 | Showing as 56 on lse. | impala391 | |
28/8/2014 10:27 | Showing as zero share price on iii? | stav5001 | |
15/8/2014 18:47 | Herds gone then! | impala391 | |
08/8/2014 17:35 | They only drop it because of the options IMO. Lol Still he whoever he or she was got a nice! | impala391 | |
04/8/2014 17:06 | andrbea 25 Jul'14 - 09:12 - 92 of 102 0 1 15% today really illiquid this one.... what would it do if the herd were to arrive? Well now we know lol.😎 | impala391 | |
03/8/2014 18:11 | Interesting read, for anyone who wants to know what TILS is upto. Hxxp://cardiffstuden | impala391 | |
27/7/2014 00:22 | What a graph! If only RGT could have looked like that, we have been diluted to Kingdom come, but it is good to see some value and hope here at last for the longterm holders. Not much but better than nothing. | stav5001 | |
26/7/2014 17:01 | Prof. Di Fiore has an alliance with TILS The former has a new article (co-author/mentor perhaps) in the literature: hxxp://jcb.rupress.o | andrbea | |
25/7/2014 13:35 | lol! ... another 15 quid ish to go and i'll be in profit :)) | stew99 | |
25/7/2014 11:55 | i suppose the up side is, these are free for us RGT holders...or are they :) | mdavies238 | |
25/7/2014 11:40 | It is expected for rgt holders to be sceptical, but ! ? # What a whoosh | rovi67 | |
25/7/2014 11:07 | jump on the same band wagon RGT had 10 years ago... and still waiting | mdavies238 | |
25/7/2014 10:31 | What would it do if a positive bit of news were to be released.🙀 | impala391 | |
25/7/2014 09:12 | 15% today really illiquid this one.... what would it do if the herd were to arrive? | andrbea | |
24/7/2014 20:30 | Once bitten, twice shy.... I have a few and I am glad to see a few more posts here. | stav5001 | |
24/7/2014 16:45 | welcome aboard Indyanna | andrbea | |
24/7/2014 15:41 | As a former RGT/ADI holder wasn't sure about this but decided to average down and topped up at 42p. Enjoying the ride and only 89 posts since April. Very low volume, imagine what could happen if the rampers/herd arrive. That's my post for the year. Going back to watch mode | indyanna | |
24/7/2014 15:27 | tils 14% getting the recognition it deserves (for a lowly mkt cap 5.4m) remeber the credentials of our advisor: "... who has linked his name to the discovery of Aventis, the world's most widely used anticancer drug, sold 7 billion dollars in 2013 alone". | andrbea | |
24/7/2014 14:09 | which is already the encouraging developments. " The project concerns the biotechnology drugs for treatment and diagnosis cancer, particularly breast cancer. Initially, the company has funded a search of a trio of scientists from the University of Cardiff, the Italian Andrea Brancale and the British Richard Clarkson and Andrew Westwell, which continues today with positive results. Following the radius of the research has expanded, always on the double track of the earliest possible diagnosis and treatment for overt tumors in advanced stage. In May, he was named president of the group dell'advisoryboard Napoleone Ferrara, a professor and researcher at the Cancer Center of the University of California San Diego who has linked his name to the discovery of Aventis, the world's most widely used anticancer drug, sold 7 billion dollars in 2013 alone. So, a few days ago, Tiziana Life has entered into an agreement with the team of Pier Paolo Di Fiore, professor of medicine at the University of Milan and associate at the European Institute of Oncology was founded by Umberto Veronesi, who is carrying out a research on stem cells of breast cancers. "A tumor can be compared - explains the Flower - a beehive composed in large part of worker bees, that being infertile can not repopulate. The growth function is the prerogative of the queen bees, the only ones able to proliferate. Stem cells are indeed the queens of the tumor. The number of stem cell-queens present in a tumor predicts how quickly it will grow and how aggression. Stem cells are the target selective short to reach to strike at the heart of the tumor in an attempt to eradicate it. " The search for Di Fiore is oriented both to the front of the diagnostic to that of the therapy. First, it is more advanced, "We have found new" markers "specific that allow us to make a faster and more accurate prognosis. Now we are aiming to get to the clinic to bring the results of our research from laboratory tests to medical practice. Just at this stage is crucial to succeed a company, in this case the fact Tiziana, who then will decide and fund the equally important part of the commercialization and marketing. " taken from hxxp://www.repubblic | andrbea | |
24/7/2014 11:19 | our advisor has a post in Califonia too The program closes with the presentation of the Rell Sunn Award. The 2014 honoree is Napoleone Ferrara, M.D., a world-renowned molecular biologist, who is credited with helping decipher how tumors grow. Ferrara currently serves as senior deputy director for basic science at UC San Diego Moores Cancer Center. hxxp://www.midaslett | andrbea |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions